Literature DB >> 12124870

Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts.

A Leask1, D J Abraham, D R Finlay, A Holmes, D Pennington, X Shi-Wen, Y Chen, K Venstrom, X Dou, M Ponticos, C Black, C Bernabeu, J K Jackman, P R Findell, M K Connolly.   

Abstract

OBJECTIVE: As an initial approach to understanding the basis of the systemic sclerosis (SSc; scleroderma) phenotype, we sought to identify genes in the transforming growth factor beta (TGF beta) signaling pathway that are up-regulated in lesional SSc fibroblasts relative to their normal counterparts.
METHODS: We used gene chip, differential display, fluorescence-activated cell sorter, and overexpression analyses to assess the potential role of TGF beta signaling components in fibrosis. Fibroblasts were obtained by punch biopsy from patients with diffuse cutaneous SSc of 2-14 months' duration (mean 8 months) and from age- and sex-matched healthy control subjects.
RESULTS: Unexpectedly, we found that fibroblasts from SSc patients showed elevated expression of the endothelial cell-enriched TGF beta receptor endoglin. Endoglin is a member of the nonsignaling high-affinity TGF beta receptor type III family. The expression of endoglin increased with progression of disease. Transfection of endoglin in fibroblasts suppressed the TGF beta-mediated induction of connective tissue growth factor promoter activity.
CONCLUSION: SSc is characterized by overproduction of matrix; that is, genes that are targets of TGF beta signaling in normal fibroblasts. Our findings suggest that lesional SSc fibroblasts may overexpress endoglin as a negative feedback mechanism in an attempt to block further induction of profibrotic genes by TGF beta.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124870     DOI: 10.1002/art.10333

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  46 in total

Review 1.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

2.  MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma.

Authors:  Honglin Zhu; Yisha Li; Shunlin Qu; Hui Luo; Yaou Zhou; Yanping Wang; Hongjun Zhao; Yunhui You; Xianzhong Xiao; Xiaoxia Zuo
Journal:  J Clin Immunol       Date:  2012-02-04       Impact factor: 8.317

3.  Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin.

Authors:  Raffaele De Palma; Francesco Del Galdo; Salvatore Lupoli; Paolo Altucci; Gianfranco Abbate; Gabriele Valentini
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

4.  Possible strategies for anti-fibrotic drug intervention in scleroderma.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-01-29       Impact factor: 5.782

5.  Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts.

Authors:  Erin Morris; Izabela Chrobak; Andreea Bujor; Faye Hant; Christine Mummery; Peter Ten Dijke; Maria Trojanowska
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

6.  Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure.

Authors:  Navin K Kapur; Kevin S Heffernan; Adil A Yunis; Peter Parpos; Michael S Kiernan; Nikhil A Sahasrabudhe; Carey D Kimmelstiel; David A Kass; Richard H Karas; Michael E Mendelsohn
Journal:  Am J Cardiol       Date:  2010-12-15       Impact factor: 2.778

Review 7.  Role of endoglin in fibrosis and scleroderma.

Authors:  Janita A Maring; Maria Trojanowska; Peter ten Dijke
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 8.  Epithelial-mesenchymal transition in tissue repair and fibrosis.

Authors:  Rivka C Stone; Irena Pastar; Nkemcho Ojeh; Vivien Chen; Sophia Liu; Karen I Garzon; Marjana Tomic-Canic
Journal:  Cell Tissue Res       Date:  2016-07-27       Impact factor: 5.249

Review 9.  Noncanonical transforming growth factor beta signaling in scleroderma fibrosis.

Authors:  Maria Trojanowska
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

10.  Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis.

Authors:  Jo Nadine Fleming; Howard M Shulman; Richard A Nash; Pamela Y Johnson; Thomas N Wight; Allen Gown; Stephen M Schwartz
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.